RT Journal Article
T1 Predictive algorithms for adjuvant therapy: TransATAC
A1 Dowsett, Mitch
A1 Salter, Janine
A1 Zabaglo, Lila
A1 Mallon, Elizabeth
A1 Howell, Antony
A1 Buzdar, Aman U.
A1 Forbes, John
A1 Pineda Sanjuan, Silvia
A1 Cuzick, Jack
A2 Penning, T. M.
AB Estrogen receptor (ER) positive primary breast cancers have a wide range of clinical outcomes. Prediction of the likely course of the disease aids treatment decision-making. In the translational arm of the ATAC (anastrozole or tamoxifen alone or combined) trial (TransATAC) we have assessed individual and multiparameter biomarkers for their prediction of overall and distant recurrence. None of the biomarkers identified differential benefit for anastrozole versus tamoxifen. Each of ER, PgR, HER2 and Ki67 was associated with risk of recurrence. A combination of these to create a single predictor IHC4 was as informative as the 21-gene recurrence score (RS). Integration of each of these molecular profiles with classical clinicopathologic variables provided the most accurate prediction of outcome
PB Elsevier
SN 0039-128X
YR 2011
FD 2011
LK https://hdl.handle.net/20.500.14352/97407
UL https://hdl.handle.net/20.500.14352/97407
LA eng
NO Dowsett, M. et al. (2011) «Predictive algorithms for adjuvant therapy: TransATAC», en Steroids, pp. 777-780. doi:10.1016/J.STEROIDS.2011.02.032
NO Breakthrough Breast Cancer (Reino Unido)
NO AstraZeneca
DS Docta Complutense
RD 6 abr 2025